Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VLX 1005

Next Previous
Drug Profile

VLX 1005

Alternative Names: CAD-1005; ML-355; VLX-1005

Latest Information Update: 27 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eastern Virginia Medical School; National Institutes of Health (USA); Thomas Jefferson University; University of California
  • Developer University of Michigan; Veralox Therapeutics
  • Class Amines; Antihyperglycaemics; Antithrombotics; Benzothiazoles; Small molecules; Sulfonamides
  • Mechanism of Action 12-lipoxygenase inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Heparin-induced thrombocytopenia and thrombosis syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Heparin-induced thrombocytopenia and thrombosis syndrome
  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 24 Feb 2026 Efficacy data from the phase II ALATHEA trial in Heparin-induced thrombocytopenia and thrombosis syndrome released by Cadrenal Therapeutics
  • 28 Jan 2026 No recent reports of development identified for preclinical development in Heparin-induced-thrombocytopenia-and-thrombosis-syndrome in USA (PO)
  • 12 Jan 2026 Cadrenal Therapeutics intends to discuss the design of a potential pivotal phase III registration study in Heparin-induced thrombocytopenia and thrombosis syndrome with the US FDA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top